Proxy firms Glass Lewis, ISS back Allergan in fight against Appaloosa
Published Apr 15, 2019 09:59AM ET
Proxy firms Glass Lewis, ISS back Allergan in fight against Appaloosa
By Manas Mishra
(Reuters) - Two major shareholder advisory firms urged investors to vote against billionaire investor David Tepper's hedge fund demand that Allergan (NYSE:AGN) Plc immediately split the roles of chief executive officer and chairman, in a boost to the Botox maker.
The recommendation from Institutional Shareholder Services LP and Glass Lewis & Co against the proposal of Tepper's Appaloosa gives firepower to Allergan Chairman and CEO Brent Saunders ahead of the drugmaker's shareholder meeting on May 1.
"Their recommendations affirm our position that our plan to adopt separate Chair and CEO positions with the next leadership transition is the best approach for Allergan shareholders," Allergan said in a statement.
However, an analyst said the recommendations were contrary to the views of many investors.
"This news is likely to frustrate a sizeable group of shareholders and we continue to await the result of the vote," RBC Capital Markets analyst Randall Stanicky said.
Appaloosa has been pressing Allergan since last year to separate the two roles, and asked for an immediate split after Allergan said an independent member of its board would be chairman, but only at its next leadership change.
Both the proxy firms said that an immediate separation of the roles was not necessary.
"There are no significant concerns regarding the board's current leadership structure sufficient to suggest that an immediate split of the CEO and chairman roles is warranted at this time rather than at the next CEO transition," ISS was quoted as saying in the Allergan statement.
Appaloosa said ISS' recommendations were "baffling" as they were inconsistent with the firm's support for a similar proposal last year, and asked shareholders to vote for its proposal.
Allergan, under pressure to rescue the company's falling stock prices, launched a review of its strategy last year. But that review is likely to result in the sale of its relatively small infectious disease unit.
Appaloosa has voiced its discontent with the results of the review, and has called for a breakup or sale of the company, citing recent clinical failures such as that of its depression treatment rapastinel.
Get The News You Want
Allergan's shares have fallen about 12 percent in the past 12 months. They trade nearly 60 percent below their record high of $340.33 in 2015.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.